CN105943674B - A kind of Chinese materia medica preparation and preparation method thereof for preventing and treating Alzheimer disease - Google Patents

A kind of Chinese materia medica preparation and preparation method thereof for preventing and treating Alzheimer disease Download PDF

Info

Publication number
CN105943674B
CN105943674B CN201610460660.7A CN201610460660A CN105943674B CN 105943674 B CN105943674 B CN 105943674B CN 201610460660 A CN201610460660 A CN 201610460660A CN 105943674 B CN105943674 B CN 105943674B
Authority
CN
China
Prior art keywords
parts
preparation
medicine composition
chinese medicine
bezoar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201610460660.7A
Other languages
Chinese (zh)
Other versions
CN105943674A (en
Inventor
曾永长
吴正治
梁少瑜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wu Zhengzhi
Shenzhen Jintai Pharmaceutical Technology LP
Original Assignee
Shenzhen Institute of Gerontology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Institute of Gerontology filed Critical Shenzhen Institute of Gerontology
Priority to CN201610460660.7A priority Critical patent/CN105943674B/en
Publication of CN105943674A publication Critical patent/CN105943674A/en
Application granted granted Critical
Publication of CN105943674B publication Critical patent/CN105943674B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/754—Evodia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/413—Gall bladder; Bile
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/41—Crassulaceae (Stonecrop family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/718—Coptis (goldthread)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention provides a kind of for preventing and treating the Chinese medicine composition of Alzheimer disease, comprising: 30-70 parts of the coptis, 5-40 parts of evodia rutaecarpa, 60-100 parts of uncaria, 10-50 parts of American Ginseng, 30-70 parts of root of kirilow rhodiola, 20-60 parts of Phytolacca acinosa flower, 0.5-5 parts of cow-bezoar and 0.05-3 parts of borneol.The present invention also provides using Chinese materia medica preparation made of the Chinese medicine composition and preparation method thereof.The present invention can significantly improve the ability of learning and memory and cognition dysfunction of a variety of AD pathological models such as spontaneous AD model mice, curative for effect in terms for the treatment of fire derived from stagnation of liver-QI type AD, have huge application prospect.

Description

A kind of Chinese materia medica preparation and preparation method thereof for preventing and treating Alzheimer disease
Technical field
The invention belongs to field of medicaments, and in particular to a kind of for preventing and treating the Chinese traditional medicine composition of Alzheimer disease Object, Chinese materia medica preparation and preparation method thereof.
Background technique
China has entered aging population society, and statistical data is shown, by the end of the year 2014,60 years old Chinese or more the elderly Mouth up to 2.12 hundred million, accounts for the 15.5% of total population, and China becomes the aged big country in the whole world.It is reported that the elderly of global over-65s In, 10% suffers from senile dementia, and 80 years old or more illness rate is up to 20%.Senile dementia (Alzheimer disease Alzheimer's disease, abbreviation AD) have become the fourth-largest killer of the mankind after heart disease, cancer, apoplexy.Epidemic disease Investigation display is learned, China's at least 6,000,000 or more patients with Alzheimer disease, annual medical expenses are at least at 30,000,000,000 yuan or more.
Alzheimer disease, pathogenesis is still unintelligible, modern research shows that the disease is more by body heredity, internal and external factor etc. The influence of gene and Multi-environment factor, characteristic pathology variation show as regioselectivity neuronal death, extracellular β-shallow lake Powder sample peptide (amyloid beta, A β) aggregation forms the Tau albumen aggregation of senile plaque (SP) and intracellular abnormal Phosphorylation It is formed neurofibrillary tangles (NFTs).At present to the understanding of AD pathogenesis with beta-amyloid polypeptide (β-amyloid Peptide, A β) theory occupies an leading position, it is believed that and A β exception excess generation, the formation of SP and NFT may in AD occurrence and development Play key effect.Meanwhile the generation of AD is also and radical damage, neurotransmitter of cholinergic neuron losing reduces and nerve Trophic factors lacks, the metal ions metabolic disorder such as calcium, iron, aluminium, copper, the endocrines such as estrogen level reduction, insulin resistance There are substantial connections for imbalance etc..Therefore, AD is a kind of typical multifactor complex disease.
For the pathogenesis of Alzheimer disease, therapeutic agent mainly has anticholinesterase, paddy currently on the market Propylhomoserin receptor antagonist, calcium ion antagonist, free radical scavenger and antioxidant, estrogen etc..Said medicine mainly with Based on chemical drugs, toxic side effect is larger.It is pointed out in 2010 European " about AD treatment guidelines ", first choice choline when AD drug therapy Esterase inhibitor.But Long-term taking medicine is needed by AD, and anticholinesterase generally requires dosage after taking for a long time and can be only achieved Desired effect.In view of current Western medicine to the limitation and adverse reaction of AD therapeutic effect, the complexity of AD etiology and pathogenesis is sufficiently sent out The characteristic and advantage of traditional Chinese medicine are waved, whole synthesis medical treatment, too many levels, multiple target point play a role, therefore research and develop safe and effective The new Chinese medicine of Alzheimer disease is prevented and treated, it is imperative, it is also extremely urgent.
Summary of the invention
The invention reside in deficiency in the prior art is overcome, provide that a kind of toxic side effect is small, treatment A Er curative for effect The Chinese materia medica preparation and preparation method thereof of Zi Haimo disease.
It provides a kind of for preventing and treating the Chinese medicine composition of Alzheimer disease in the first aspect of the invention, presses According to parts by weight meter, the Chinese medicine composition includes: 30-70 parts of the coptis, such as 32 parts, 35 parts, 40 parts, 45 parts, 50 parts, 55 Part, 60 parts, 65 parts etc.；5-40 parts of evodia rutaecarpa, such as 8 parts, 10 parts, 15 parts, 20 parts, 25 parts, 30 parts, 35 parts, 38 parts etc.；Uncaria 60-100 parts, such as 64 parts, 68 parts, 75 parts, 80 parts, 86 parts, 90 parts, 93 parts, 98 parts etc.；10-50 parts of American Ginseng, such as 13 Part, 18 parts, 22 parts, 27 parts, 30 parts, 35 parts, 40 parts, 45 parts etc.；30-70 parts of root of kirilow rhodiola, such as 32 parts, 35 parts, 40 parts, 45 Part, 50 parts, 55 parts, 60 parts, 65 parts etc.；20-60 parts of Phytolacca acinosa flower, such as 22 parts, 25 parts, 30 parts, 35 parts, 40 parts, 45 parts, 50 Part, 55 parts etc.；0.5-5 parts of cow-bezoar, such as 0.8 part, 1 part, 1.5 parts, 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts, 4.5 parts etc.；With 0.05-3 parts of borneol, such as 0.08 part, 0.12 part, 0.15 part, 0.2 part, 0.25 part, 1 part, 3 parts etc..
Preferably, the Chinese medicine composition includes: 40-60 parts of the coptis, 10-30 parts of evodia rutaecarpa, 70-90 parts of uncaria, the West 20-40 parts of ginseng, 40-60 parts of root of kirilow rhodiola, 30-50 parts of Phytolacca acinosa flower, 1-3 parts of cow-bezoar and 0.1-2 parts of borneol.
It is further preferred that the Chinese medicine composition includes: 50 parts of the coptis, 20 parts of evodia rutaecarpa, 80 parts of uncaria, American Ginseng 30 Part, 50 parts of root of kirilow rhodiola, Phytolacca acinosa spend 40 parts, 2 parts of cow-bezoar and 1 part of borneol.
The second aspect of the invention is to provide a kind of for preventing and treating the system of the drug ingedient of Alzheimer disease Preparation Method is prepared using any one Chinese medicine composition described in first aspect of the present invention as raw material.
Preferably, the preparation method comprises the following steps: by each pulverizing medicinal materials to obtain the final product.
In this case it is also possible to various preparations will further be made, such as capsule, pill, tablet etc..In preparation Pharmaceutically acceptable auxiliary material can be added in the process, auxiliary material can also be not added.
Preferably, the preparation method comprises the following steps: step 1, American Ginseng, cow-bezoar and borneol being crushed；Using water Formulation extracts the coptis, evodia rutaecarpa, uncaria, root of kirilow rhodiola and Phytolacca acinosa flower, obtains water extract；Step 2, step 1 is obtained Crushed material and water extract mix to obtain the final product.
In this case it is also possible to various preparations will further be made, such as capsule, pill, tablet etc..In preparation Pharmaceutically acceptable auxiliary material can be added in the process, auxiliary material can also be not added.
Preferably, the preparation method comprises the following steps: step a, and cow-bezoar and borneol are crushed；Using water extraction to west American ginseng, the coptis, evodia rutaecarpa, uncaria, root of kirilow rhodiola and Phytolacca acinosa flower extract, and obtain water extract；Step b, the powder that step a is obtained It minces and is mixed with water extract to obtain the final product.
In this case it is also possible to various preparations will further be made, such as capsule, pill, tablet, liquid preparation Deng.Pharmaceutically acceptable auxiliary material can be added in production process, auxiliary material can also be not added.
The third aspect of the invention is to provide a kind of for preventing and treating the Chinese materia medica preparation of Alzheimer disease, work Property component include the drug being prepared as a raw material using the work of any one Chinese medicine composition described in first aspect of the present invention The drug ingedient of the preparation of any one preparation method described in ingredient or the second aspect of the present invention.
It should be understood that the Chinese materia medica preparation can prevent with other treatment and/or treat the medicine of Alzheimer disease Object compatible use.
It should be understood that the Chinese materia medica preparation can be capsule, pill, tablet, liquid preparation, patch etc..According to dosage form Needs, pharmaceutically acceptable auxiliary material is added to the property of can choose, auxiliary material can also be not added.
Preferably, the Chinese materia medica preparation further includes pharmaceutically acceptable auxiliary material.
The fourth aspect of the invention is to provide any one Chinese medicine composition described in first aspect of the present invention or sheet Appoint described in the drug ingedient or third aspect of the present invention of the preparation of any one preparation method described in invention the second aspect It anticipates a kind of application of Chinese materia medica preparation in the drug of preparation prevention and/or treatment Alzheimer disease.
The present invention is based on the Basic disease cause and treatment method of existing stagnated fire type AD, in conjunction with long-term diagnosis and treatment AD clinical experience, And it is studied through many years Pharmacodynamics screening.Clinical verification through many years, it is curative for effect.Serial pharmacodynamic study shows, this Invention can significantly improve the ability of learning and memory and cognition dysfunction of a variety of AD pathological models such as spontaneous AD model mice, Mechanism and inhibition AD key pathological product A β and Phosphorylated tau are generated, enhancing central cholinergic system is active, activating ELK 1 B Access, anti-inflammatory, anti-oxidant, anti-apoptotic, protection neuron, promotion nerve regneration, improvement synaptic plasticity etc. are directly related.This hair It is bright curative for effect in terms for the treatment of fire derived from stagnation of liver-QI type AD, there is huge application prospect.
Specific embodiment
Below with reference to specific embodiment, the present invention is further illustrated, to better understand the invention.
Embodiment 1
Take raw material: coptis 5g, evodia rutaecarpa 2g, uncaria 8g, American Ginseng 3g, root of kirilow rhodiola 5g, Phytolacca acinosa flower 4g, cow-bezoar 0.2g, dragon Brain 0.1g.Each pulverizing medicinal materials are encapsulated (it should be understood that the present embodiment can also be using pharmaceutically common side at fine powder Pill, tablet, dripping pill etc. is made in method).
Embodiment 2
Take raw material: coptis 5g, evodia rutaecarpa 2g, uncaria 8g, American Ginseng 3g, root of kirilow rhodiola 5g, Phytolacca acinosa flower 4g, cow-bezoar 0.2g, dragon Brain 0.1g.It is spare that American Ginseng, cow-bezoar and borneol are ground into fine powder.The coptis, evodia rutaecarpa, uncaria, root of kirilow rhodiola, Phytolacca acinosa, which are spent etc., adds water It 8-16 times (weight), decocts 1 hour, filtering, filtrate is spare；Filter residue adds 8-16 times of (weight) water, decocts 1 hour, filtering, Filter residue is discarded, previous filtrate is merged, is concentrated, it is dry, dry extract is made；By dry extract and American Ginseng, cow-bezoar and borneol Fine powder is mixed evenly, granulation or piller, encapsulated (it should be understood that the present embodiment can also be using pharmaceutically common side Pill, tablet etc. is made in method).
Embodiment 3
Take raw material: coptis 5g, evodia rutaecarpa 2g, uncaria 8g, American Ginseng 3g, root of kirilow rhodiola 5g, Phytolacca acinosa flower 4g, cow-bezoar 0.2g, dragon Brain 0.1g.American Ginseng, the coptis, evodia rutaecarpa, uncaria, root of kirilow rhodiola, Phytolacca acinosa are spent etc. and added 8-16 times of water (weight), is decocted 1 hour, mistake Filter, filtrate are spare；Filter residue adds 8-16 times of (weight) water, decocts 1 hour, and filtering discards filter residue, merges previous filtrate, dense Contracting；Cow-bezoar and borneol is added, suitable additive is then added and purified water is deployed to normal concentration, the liquid systems such as mixture are made Agent.
Embodiment 4
The present embodiment is different as the proportion of raw material from the difference of embodiment 1.The raw material of the present embodiment are as follows: the coptis 4g, evodia rutaecarpa 3g, uncaria 7g, American Ginseng 4g, root of kirilow rhodiola 6g, Phytolacca acinosa flower 3g, cow-bezoar 0.3g, borneol 0.01g.
Embodiment 5
The present embodiment is different as the proportion of raw material from the difference of embodiment 2.The raw material of the present embodiment are as follows: the coptis 4g, evodia rutaecarpa 3g, uncaria 7g, American Ginseng 4g, root of kirilow rhodiola 6g, Phytolacca acinosa flower 3g, cow-bezoar 0.3g, borneol 0.01g.
Embodiment 6
The present embodiment is different as the proportion of raw material from the difference of embodiment 3.The raw material of the present embodiment are as follows: the coptis 4g, evodia rutaecarpa 3g, uncaria 7g, American Ginseng 4g, root of kirilow rhodiola 6g, Phytolacca acinosa flower 3g, cow-bezoar 0.3g, borneol 0.01g.
Embodiment 7
The present embodiment is different as the proportion of raw material from the difference of embodiment 1.The raw material of the present embodiment are as follows: the coptis 6g, evodia rutaecarpa 1g, uncaria 9g, American Ginseng 2g, root of kirilow rhodiola 4g, Phytolacca acinosa flower 5g, cow-bezoar 0.1g, borneol 0.2g.
Embodiment 8
The present embodiment is different as the proportion of raw material from the difference of embodiment 2.The raw material of the present embodiment are as follows: the coptis 6g, evodia rutaecarpa 1g, uncaria 9g, American Ginseng 2g, root of kirilow rhodiola 4g, Phytolacca acinosa flower 5g, cow-bezoar 0.1g, borneol 0.2g.
Embodiment 9
The present embodiment is different as the proportion of raw material from the difference of embodiment 3.The raw material of the present embodiment are as follows: the coptis 6g, evodia rutaecarpa 1g, uncaria 9g, American Ginseng 2g, root of kirilow rhodiola 4g, Phytolacca acinosa flower 5g, cow-bezoar 0.1g, borneol 0.2g.
Embodiment 10
The present embodiment is different as the proportion of raw material from the difference of embodiment 1.The raw material of the present embodiment are as follows: the coptis 3g, evodia rutaecarpa 4g, uncaria 6g, American Ginseng 1g, root of kirilow rhodiola 7g, Phytolacca acinosa flower 2g, cow-bezoar 0.5g, borneol 0.05g.
Embodiment 11
The present embodiment is different as the proportion of raw material from the difference of embodiment 2.The raw material of the present embodiment are as follows: the coptis 3g, evodia rutaecarpa 4g, uncaria 6g, American Ginseng 1g, root of kirilow rhodiola 7g, Phytolacca acinosa flower 2g, cow-bezoar 0.5g, borneol 0.05g.
Embodiment 12
The present embodiment is different as the proportion of raw material from the difference of embodiment 1.The raw material of the present embodiment are as follows: the coptis 7g, evodia rutaecarpa 0.5g, uncaria 10g, American Ginseng 5g, root of kirilow rhodiola 3g, Phytolacca acinosa flower 6g, cow-bezoar 0.05g, borneol 0.04g.
Embodiment 13
The present embodiment is different as the proportion of raw material from the difference of embodiment 3.The raw material of the present embodiment are as follows: the coptis 7g, evodia rutaecarpa 0.5g, uncaria 10g, American Ginseng 5g, root of kirilow rhodiola 3g, Phytolacca acinosa flower 6g, cow-bezoar 0.05g, borneol 0.04g.
One, to Memory acquisition, consolidate and reproduce the function and effect of obstacle pathological model
1 experimental animal
Kunming mouse 600, male, 3 monthly ages are purchased from No.1 Military Medical Univ.'s Experimental Animal Center.
2 grouping administrations
Kunming mouse 200, it is randomly divided into 5 groups, the 1st group is Normal group, and the 2nd group is model control group, the 3rd group For western medicine group, the 4th group is small dose group, and the 5th group is large dosage of group.3rd group is given Hydergine 0.6mg/kg, the 4, the Chinese materia medica preparation 6.23g/Kg and 18.69g/Kg that embodiment 1 obtains are given respectively for 5 groups.It grinds above and is made into 0.5ml liquid Gastric infusion, continuous 7d, Normal group and model control group are filled with equivalent DW.Memory acquisition, memory consolidation, memory reproduce The grouping of 3 experiments is administered with this scheme.
The preparation of 3 dysmnesia models and recall tests
Memory acquisition experiment is after observation 6d administration 1h, each model group SCPL(Scopolamine, hyoscine) 3mg/ Kg is injected intraperitoneally, and starts step dow n test training after 10min, tests Memory result after 7d administration 1h；Memory consolidation is tested in observation 6d carries out diving tower training after 1h is administered, and cycloheximide (Cycloheximide) is injected intraperitoneally in each model group immediately after training Memory result is tested after 120mg/kg, 7d administration 1h；Remember reproduction experiments and carries out darkness avoidance test instruction after observation 6d administration 1h Practice, each 40% ethyl alcohol 0.1ml/10g weight of model group stomach-filling after 30min is administered in 7d, tests Memory result after 30min.
The test of 4 learning and memory functions
4.1 step dow n tests (Step-down test): dynamic with MR-92l type mouse Jumping test automatic recording instrument test experience The Memory acquisition and memory consolidation ability of object.
Mouse is placed in diving tower instrument first, after adapting to environment 5min, is put down gently on platform, when animal jumps off from diving tower Four limbs give the stimulation of 40V alternating voltage when contacting copper grid, record mouse escapes the incubation period (Escape to platform Latency, EL) and the electric shock number (errors number) in 5min is recorded, in this, as school grade.It is tested afterwards for 24 hours, On mouse horizontalization platform, will record in incubation period (Step-down Latency) that it is rested on security platform and its 3min by The number (errors number) of electric shock evaluates it with this and remembers note ability.When test, if mouse rests on platform more than 3min, Incubation period is in terms of 180s.
4.2 darkness avoidance tests: with the memory reproduction of the unidirectional shuttle box observation experiment animal of DS-2 mouse acousto-optic.
Mouse face is put into bright room backwards to hole when experiment.Start timer simultaneously, animal passes through hole and enters darkroom It is shocked by electricity, timing is automatically stopped, and takes out mouse.Record mouse enters the time needed for darkroom encounters electric shock from the bright room of people is put, This is incubation period.It is test again after for 24 hours.Record enters the number of animals in darkroom, is electrically shocked number (mistake in incubation period and 5min Number) be averaged, darkroom person is not entered in 5min, incubation period is in terms of 300s.
5 experimental results
Influence of the present invention to memory acquisition disturbance is shown in Table 1, and the influence to memory consolidation obstacle is shown in Table 2, reproduces to memory The influence of obstacle is shown in Table 3.
Improvement result (be averaged) of 1 present invention of table to SCPL memory acquisition disturbance
Effect (be averaged) of 2 present invention of table to memory consolidation Disorder Model
Effect (be averaged) of 3 present invention of table to reproducibility dysmnesia model
The experimental results showed that the present invention is to Memory acquisition caused by hyoscine, cycloheximide and ethyl alcohol, consolidation and reproduction Obstacle improves significantly and antagonism.And it is substantially better than Western medicine Hydergine control group.
Example 2-13 is tested according to above-mentioned experimental method, as a result substantially with embodiment 1, all to Anisodus luridus It Memory acquisition caused by alkali, cycloheximide and ethyl alcohol, consolidation and reproduces obstacle and improves significantly and antagonism.
Two, to the influence of spontaneous Alzheimer-like Disease Model cognitive function
1 experimental animal
Kunming mouse, male, 13 monthly ages are purchased from Zhongshan Medical Univ.'s Experimental Animal Center.Raising is screened to 21 monthly ages Old cognitive disorder model (memory disorders) mouse.
The screening technique of 2 old cognitive disorder model mouses
Under 95% and 99% range of normal value of young mouse Jumping test recall tests average security platform incubation period (SDL) Limit value is boundary, and incubation period is old cognitive disorder model mouse less than 99% fiducial limit lower limit value person, is greater than 95% fiducial limit lower limit value For senility study remember normal mice, incubation period between two lower limit values person be it is suspicious, eliminate experiment.
.3 grouping administration
Old cognitive disorder model mouse 200 filtered out, are randomly divided into 4 groups, and every group 50, respectively blank control Group, western medicine group, small dose group, large dosage of group.Normal group of senility study memory (referred to as normal group old, similarly hereinafter) is separately set to do For Normal group, Normal group is done with 50 senility study filtered out memory normal mices.Western medicine group is given Hydergine 0.6mg/Kg, small, large dosage of group is given embodiment 1 6.80g/Kg and 20.41g/Kg respectively, the above equal bedding-in at 0.5ml liquid gastric infusion, continuous 60d, Normal group and blank control group are filled with same amount of normal saline.
3 experimental methods
Administration is given according to upper method.Administration observation the 59th day carries out diving tower training, tests after second day administration 1h after perfusion 1h Memory result.With MR-921 type mouse Jumping test automatic recording instrument with step down test (step-down test) detection study and Memory result.
4 experimental results
Influence of the present invention to old cognitive disorder model mouse learning and memory is shown in Table 4.
Improvement result (average value) of the table 4 to spontaneous old cognitive disorder model learning memory
The experimental results showed that the present invention improves significantly to spontaneous senile dementia.And it is substantially better than Western medicine Hydergine control group.
Example 2-13 is tested according to above-mentioned experimental method, as a result substantially with embodiment 1, all to spontaneous old Year property dementia improves significantly.
Specific embodiments of the present invention are described in detail above, but it is merely an example, the present invention is simultaneously unlimited It is formed on particular embodiments described above.To those skilled in the art, any couple of present invention carries out equivalent modifications and Substitution is also all among scope of the invention.Therefore, without departing from the spirit and scope of the invention made by equal transformation and Modification, all should be contained within the scope of the invention.

Claims (10)

1. a kind of for preventing and treating the Chinese medicine composition of Alzheimer disease, which is characterized in that in parts by weight, institute It is composed of the following components to state Chinese medicine composition: 30-70 parts of the coptis, 5-40 parts of evodia rutaecarpa, 60-100 parts of uncaria, American Ginseng 10-50 Part, 20-60 parts of 30-70 parts of root of kirilow rhodiola, Phytolacca acinosa flower, 0.5-5 parts of cow-bezoar and 0.05-3 parts of borneol.
2. Chinese medicine composition according to claim 1, which is characterized in that the Chinese medicine composition is composed of the following components: 40-60 parts of the coptis, 10-30 parts of evodia rutaecarpa, 70-90 parts of uncaria, 20-40 parts of American Ginseng, 40-60 parts of root of kirilow rhodiola, Phytolacca acinosa flower 30- 50 parts, 3 parts of cow-bezoar 1- and 0.1-2 parts of borneol.
3. Chinese medicine composition according to claim 2, which is characterized in that the Chinese medicine composition is composed of the following components: 50 parts of the coptis, 20 parts of evodia rutaecarpa, 80 parts of uncaria, 30 parts of American Ginseng, 50 parts of root of kirilow rhodiola, Phytolacca acinosa spend 40 parts, 2 parts of cow-bezoar and borneol 1 Part.
4. a kind of for preventing and treating the preparation method of the drug ingedient of Alzheimer disease, which is characterized in that wanted with right Ask Chinese medicine composition described in any one of 1-3 for raw material progress.
5. the preparation method according to claim 4, which comprises the following steps: by each pulverizing medicinal materials to obtain the final product.
6. the preparation method according to claim 4, which comprises the following steps:
Step 1, American Ginseng, cow-bezoar and borneol are crushed；Using water extraction to the coptis, evodia rutaecarpa, uncaria, root of kirilow rhodiola and Phytolacca acinosa flower It extracts, obtains water extract；
Step 2, crushed material and water extract that step 1 obtains are mixed to obtain the final product.
7. the preparation method according to claim 4, which comprises the following steps:
Step a crushes cow-bezoar and borneol；Using water extraction to American Ginseng, the coptis, evodia rutaecarpa, uncaria, root of kirilow rhodiola and Phytolacca acinosa flower It extracts, obtains water extract；
Step b mixes the obtained crushed material of step a and water extract to obtain the final product.
8. a kind of for preventing and treating the Chinese materia medica preparation of Alzheimer disease, which is characterized in that it includes using claim Chinese medicine composition described in any one of 1-3 is made any one in the drug ingedient or claim 4-7 that are prepared as a raw material The drug ingedient of preparation method preparation described in.
9. Chinese materia medica preparation according to claim 8, which is characterized in that it further includes pharmaceutically acceptable auxiliary material.
10. system described in any one of Chinese medicine composition or claim 4-7 described in any one of claim 1-3 Chinese materia medica preparation described in the drug ingedient or claim 8 or 9 of Preparation Method preparation is in preparation prevention and/or treatment alzheimer ' Application in the drug of silent disease.
CN201610460660.7A 2016-06-22 2016-06-22 A kind of Chinese materia medica preparation and preparation method thereof for preventing and treating Alzheimer disease Active CN105943674B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610460660.7A CN105943674B (en) 2016-06-22 2016-06-22 A kind of Chinese materia medica preparation and preparation method thereof for preventing and treating Alzheimer disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610460660.7A CN105943674B (en) 2016-06-22 2016-06-22 A kind of Chinese materia medica preparation and preparation method thereof for preventing and treating Alzheimer disease

Publications (2)

Publication Number Publication Date
CN105943674A CN105943674A (en) 2016-09-21
CN105943674B true CN105943674B (en) 2019-09-20

Family

ID=56903523

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610460660.7A Active CN105943674B (en) 2016-06-22 2016-06-22 A kind of Chinese materia medica preparation and preparation method thereof for preventing and treating Alzheimer disease

Country Status (1)

Country Link
CN (1) CN105943674B (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102028910A (en) * 2009-09-29 2011-04-27 丁仁松 Chinese medicinal preparation for treating Alzheimer's disease and preparation method thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102028910A (en) * 2009-09-29 2011-04-27 丁仁松 Chinese medicinal preparation for treating Alzheimer's disease and preparation method thereof

Also Published As

Publication number Publication date
CN105943674A (en) 2016-09-21

Similar Documents

Publication Publication Date Title
CN1977868B (en) Ginkgo biloba leaf total terpene lactone extract, and its preparing method, medicinal composition and use
Hu et al. Danggui-Shaoyao-San and its active fraction JD-30 improve Aβ-induced spatial recognition deficits in mice
CN102085282B (en) Traditional Chinese medicine composition for treating hypophrenia and senile dementia and preparation method and detection method thereof
CN104225167B (en) Purposes of the LIUWEI DIHUANG TANG extract in treatment dementia or cognition dysfunction
CN102119970B (en) Chinese medicinal composition for treating myasthenia gravis
CN102772469B (en) Medicine composition used for preventing or treating senile dementia
CN105943674B (en) A kind of Chinese materia medica preparation and preparation method thereof for preventing and treating Alzheimer disease
CN103735761B (en) A kind of pharmaceutical composition preventing and treating Alzheimer disease and preparation method thereof
CN107998314B (en) A Chinese medicinal composition for invigorating kidney and brain, and its preparation method
CN105168435A (en) Lucid ganoderma composition preparation, and preparation method and application thereof
CN109908201A (en) A kind of Chinese medicine composition extract and preparation process and application
CN109289009A (en) A kind of Chinese medicine composition and its preparation method and application
CN106727928A (en) Prunella vulgaris extract and preparation method and application
CN106421447B (en) A kind of pharmaceutical composition for controlling blood pressure and protecting blood vessel and its production and use
CN102631397B (en) Traditional Chinese medicine composition for improving cerebral blood circulation and preparation method thereof
Elufioye et al. Cognitive-enhancing properties of Morinda lucida (Rubiaceae) and Peltophorum pterocarpum (Fabaceae) in scopolamine-induced amnesic mice
CN100479816C (en) Gingko total terpene lactone compounded medicinal composition, and preparing method and use thereof
KR101509056B1 (en) Composition having brain function and congnition enhancing activity comprising ginseng mixed herbal extracts, ginsenoside Rg2 and ginsenoside F2
EP0652762A1 (en) Novel anxiolytic
JPH06128165A (en) Cerebral function-improving agent
CN102100776B (en) Oral administration medicament for treating dermatitis
Deng et al. CZYH Alleviates β‐Amyloid‐Induced Cognitive Impairment and Inflammation Response via Modulation of JNK and NF‐κB Pathway in Rats
CN100545163C (en) A kind of active ingredient of Chinese herbs compound and preparation and purposes of preventing and treating senile dementia
CN103432229B (en) A kind of pharmaceutical composition of senile dementia prevention and cure
CN1453029A (en) Chinese medicine composition for treating senile dementia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Wu Zhengzhi

Inventor after: Zeng Yongchang

Inventor after: Liang Shaoyu

Inventor before: Zeng Yongchang

Inventor before: Wu Zhengzhi

Inventor before: Liang Shaoyu

CP02 Change in the address of a patent holder
CP02 Change in the address of a patent holder

Address after: 518000 No. 3002, Shaanggang West Road, Huafu Street, Futian District, Shenzhen City, Guangdong Province

Patentee after: SHENZHEN INSTITUTE OF GERIATRICS

Patentee after: Wu Zhengzhi

Patentee after: Zeng Yongchang

Address before: 518000 No. 3 Dongmen North Road, Shenzhen, Guangdong, Luohu District

Patentee before: SHENZHEN INSTITUTE OF GERIATRICS

Patentee before: Wu Zhengzhi

Patentee before: Zeng Yongchang

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20210910

Address after: 518107 1301, building 1, hengtaiyu building, Tangwei community, Fenghuang street, Guangming District, Shenzhen, Guangdong

Patentee after: Shenzhen Jintai pharmaceutical technology partnership (L.P.)

Patentee after: Wu Zhengzhi

Address before: 518000 No. 3002 Sungang West Road, Futian District Huafu street, Shenzhen, Guangdong

Patentee before: SHENZHEN INSTITUTE OF GERIATRICS

Patentee before: Wu Zhengzhi

Patentee before: Zeng Yongchang